Table 2.
The accuracy of NT-proBNP and ARIC HF in identifying Stage B Heart Failure, diastolic dysfunction, reduced global longitudinal strain and left ventricular hypertrophy in the validation dataset
| NT-proBNP | ARIC HF | |||||||
|---|---|---|---|---|---|---|---|---|
| AUC (95% CI) | > 125 pg/mL (Recommended cut-off) | > 21 pg/mL (optimal cut-off) | AUC (95%CI) | > 8% (optimal cut-off) | ||||
| Sensitivity | Specificity | Sensitivity | Specificity | Sensitivity | Specificity | |||
| SBHF | 0.55 (0.43–0.66) | 14.75% | 85.25% | 85.25% | 9.68% | 0.67 (0.56–0.79) | 71.88% | 66.67% |
| DD | 0.52 (0.40–0.63) | 9.76% | 87.80% | 87.80% | 13.73% | 0.61 (0.50–0.73) | 72.09% | 51.85% |
| Reduced GLS | 0.52 (0.41–0.64) | 10.87% | 84.78% | 84.78% | 10.87% | 0.69 (0.58–0.80) | 77.55% | 60.42% |
| LVH | 0.66 (0.21–0.98) | 60% | 80.00% | 80.00% | 12.64% | 0.45 (0.22–0.67) | 60% | 41.30% |
NT-proBNP: N-terminal pro-B-type natriuretic peptide; ARIC HF: atherosclerosis Risk in Communities Heart Failure score; AUC: area under the curve; CI: confidence interval; SBHF: stage B Heart Failure; DD: diastolic dysfunction; GLS: global longitudinal strain; LVH: left ventricular hypertrophy